Screening for High Frequency Malignant Disease
NCT: NCT05117840 · ACTIVE_NOT_RECRUITING
Brief Summary
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Frequently Asked Questions
What is Screening for High Frequency Malignant Disease?
Screening for High Frequency Malignant Disease is a clinical trial registered under NCT05117840. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05117840?
The current status of NCT05117840 (Screening for High Frequency Malignant Disease) is: ACTIVE_NOT_RECRUITING.
When did Screening for High Frequency Malignant Disease start?
Screening for High Frequency Malignant Disease started on 2022-01-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.